INKT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INKT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. MiNK Therapeutics's Tax Expense for the three months ended in Dec. 2024 was $0.00 Mil. MiNK Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $-2.46 Mil. Therefore, MiNK Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 was 0.00%.
The historical data trend for MiNK Therapeutics's Tax Rate % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiNK Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Tax Rate % | Get a 7-Day Free Trial | - | - | - | - | - |
MiNK Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Tax Rate % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.
MiNK Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as
Tax Rate % | = | Tax Expense (A: Dec. 2024 ) | / | Pre-Tax Income (A: Dec. 2024 ) |
= | 0 | / | -10.785 | |
= | 0.00 % |
MiNK Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as
Tax Rate % | = | Tax Expense (Q: Dec. 2024 ) | / | Pre-Tax Income (Q: Dec. 2024 ) |
= | 0 | / | -2.463 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of MiNK Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.
Agenus Inc | 10 percent owner | 3 FORBES ROAD, LEXINGTON MA 02421 |
Garo H Armen | director | 3 FORBES ROAD, LEXINGTON MA 02421 |
Ulf Wiinberg | director | |
Brian Corvese | director | C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010 |
Christine M Klaskin | officer: Treasurer | 3 FORBES ROAD, LEXINGTON MA 02421 |
Jennifer Buell | director, officer: See Remarks | 3 FORBES ROAD, LEXINGTON MA 02421 |
Barbara Ryan | director | 22 CAVRAY ROAD, NORWALK CT 06855 |
Walter Md Flamenbaum | director | 3 FORBES ROAD, LEXINGTON MA 02421 |
John Baldoni | director | 3 FORBES ROAD, LEXINGTON MA 02421 |
Peter Behner | director | 3 FORBES ROAD, LEXINGTON MA 02421 |
Van Dijk Marcus Antonius | officer: Chief Technology Officer | 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010 |
From GuruFocus
By Marketwired • 11-11-2024
By Marketwired • 10-31-2024
By Marketwired • 12-18-2024
By Marketwired • 08-01-2024
By Marketwired • 10-04-2024
By Marketwired • 02-12-2025
By Marketwired • 04-30-2024
By Marketwired • 01-23-2025
By Marketwired • 05-13-2024
By Marketwired • 08-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.